Newsroom | 16486 results
Sorted by: Latest
-
City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting
LOS ANGELES--(BUSINESS WIRE)--Researchers with City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S. News & World Report, will present more than 74 chaired, plenary, educational, minisymposium, poster and other sessions on innovative clinical trial results, breakthrough diagnostic techniques and advances in treatment options at the AACR Annual Meeting, which st...
-
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Mini-Oral Presentation Details: Title: Efficacy and safety of the comb...
-
Talus Bio Presents Preclinical Data on Transcription Factor Therapeutic Programs at the AACR Annual Meeting 2025
SEATTLE--(BUSINESS WIRE)--Talus Bioscience, a technology-enabled therapeutics company, today announced new preclinical data from programs targeting transcription factors in chordoma, non-small cell lung cancer, and advanced prostate cancer. The data, presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, held April 25-30, support Talus Bio’s first-in-class approach to target previously undruggable transcription factors using regulome-scale discovery in live human...
-
BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours
DURHAM, N.C. & MÄNNEDORF, Switzerland--(BUSINESS WIRE)--BioSkryb Genomics and Tecan Group (SIX Swiss Exchange: TECN), today introduced a high-throughput single-cell workflow, combining BioSkryb’s 384-well format of the ResolveOME™ Whole Genome and Transcriptome Single-Cell Core Kit with the Uno Single Cell Dispenser™, provided by Tecan. The integrated solution enables parallel high-resolution analysis of hundreds to thousands of individual cells, addressing growing demand for scalable, multiomi...
-
Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including one oral presentation, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, on April 25 - 30 in Chicago. Tempus researchers will showcase scientific and clinical research that highlight the transformative impact of AI on oncology treatment an...
-
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer...
-
Iksuda to Present Growing ADC Pipeline at AACR
NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class leading, clinically validated antibody drug conjugates (ADCs) today announces that it will present three posters at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois (25-30 April). The posters cover the Company’s new payload class, the ProAlk series, its CA242-directed ADC, IKS04, being developed for the treatment of gastrointestinal (GI) cancers, and its proprietary P...
-
Sensorion Announces Presentation by Pr. Natalie Loundon at the 2025 American Society of Pediatric Otolaryngology Annual Meeting
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that Pr. Natalie Loundon, pediatric ENT Surgeon, Director of the Center for Research in Pediatric Audiology, Necker Enfants Malades Hospital, AP-HP, in Paris, France, will make an oral presentation at the annual meeting of the American Soci...
-
Sensorion annonce la tenue d’une conférence du Dr. Natalie Loundon lors de la réunion annuelle 2025 de la Société américaine d'oto-rhino-laryngologie pédiatrique ASPO
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN), société pionnière de biotechnologie au stade clinique, spécialisée dans le développement de nouvelles thérapies pour restaurer, traiter et prévenir les troubles de la perte auditive, annonce aujourd'hui que Le Dr. Natalie Loundon (Pr. CMHP), Chirurgien ORL pédiatrique, Directrice du Centre d’Implantation Cochléaire et du service d’audiologie, à l’Hôpital Necker-Enfants malades, à Paris, en France, assurera...
-
Daniel Cracchiolo Institute Opens at Steele Children’s Research Center
PHOENIX--(BUSINESS WIRE)--The Steele Foundation held a private ribbon-cutting ceremony for the new Daniel Cracchiolo Institute for Pediatric Autoimmune Disease Research....